Urogen Pharma (NASDAQ:URGN) Receives Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Urogen Pharma (NASDAQ:URGN) in a research note published on Tuesday morning,Benzinga reports. The firm currently has a $25.00 price target on the stock.

Other equities analysts have also recently issued research reports about the company. Guggenheim restated a “buy” rating and set a $30.00 target price (up previously from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. Oppenheimer set a $31.00 price objective on Urogen Pharma and gave the stock a “buy” rating in a research note on Friday, June 13th. The Goldman Sachs Group set a $16.00 target price on Urogen Pharma and gave the company a “neutral” rating in a research note on Friday, June 13th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Urogen Pharma in a research report on Tuesday, July 8th. Finally, Scotiabank restated an “outperform” rating on shares of Urogen Pharma in a report on Friday, June 13th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $32.86.

Urogen Pharma Stock Up 4.2%

Shares of Urogen Pharma stock opened at $20.72 on Tuesday. The stock has a market capitalization of $957.26 million, a P/E ratio of -6.52 and a beta of 1.12. Urogen Pharma has a 12-month low of $3.42 and a 12-month high of $21.02. The company has a 50-day simple moving average of $13.17 and a 200 day simple moving average of $11.17.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. The business had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. On average, equities analysts anticipate that Urogen Pharma will post -3.12 earnings per share for the current year.

Insider Transactions at Urogen Pharma

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,522 shares of Urogen Pharma stock in a transaction on Monday, July 28th. The stock was sold at an average price of $19.14, for a total value of $143,971.08. Following the completion of the transaction, the general counsel directly owned 41,492 shares of the company’s stock, valued at $794,156.88. The trade was a 15.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark Schoenberg sold 5,149 shares of the firm’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $19.14, for a total transaction of $98,551.86. Following the completion of the transaction, the insider directly owned 158,229 shares in the company, valued at approximately $3,028,503.06. This represents a 3.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,833 shares of company stock valued at $280,567 in the last three months. Insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On Urogen Pharma

Hedge funds have recently made changes to their positions in the stock. CWM LLC grew its position in Urogen Pharma by 6,047.1% during the 1st quarter. CWM LLC now owns 5,225 shares of the company’s stock worth $58,000 after acquiring an additional 5,140 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Urogen Pharma during the fourth quarter worth $59,000. Lazard Asset Management LLC bought a new position in Urogen Pharma during the fourth quarter worth $67,000. GAMMA Investing LLC lifted its holdings in Urogen Pharma by 6,908.4% in the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock valued at $83,000 after buying an additional 7,392 shares during the period. Finally, Aquatic Capital Management LLC bought a new stake in Urogen Pharma during the fourth quarter valued at $101,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.